However, the IL-36R agonist-treated group showed an increase in infiltrating CD8+ and CD4+ T cells in comparison to all groups, indicating that whilst both treatment regimens reduce tumour volume in vivo, alterations in tumour infiltrating immune populations were only observed in the IL-36R agonist-treated group (Fig. 5C). The gene discussed is CD4; the disease is neoplasm.